Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Patients treated with tumor-infiltrating lymphocytes saw a 50% reduction in disease progression or death.
Treatment-experienced people who received the antibody-drug conjugate lived three months longer than those who got more chemotherapy.
The Phase III FRESCO-2 trial showed an improvement in progression-free survival.
New tests can detect a common signal across more than 50 types of cancer from tumor DNA in blood.
Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.
Starting Keytruda before surgery improves the outlook for patients with Stage III-IV melanoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.